Liu Rui, Yang Fan, Ma Lixia, Guo Yuelu, Cao Miaomiao, Fu Zhonghua, Deng Biping, Zheng Qinlong, Chen Chen, Li Danyang, Ke Xiaoyan, Hu Kai
Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital, Beijing, China.
Cytology Laboratory, Beijing GoBroad Boren Hospital, Beijing, China.
Front Oncol. 2025 May 23;15:1566938. doi: 10.3389/fonc.2025.1566938. eCollection 2025.
Relapsed or refractory (R/R) Burkitt lymphoma (BL) in adults is aggressive and lacks standardized salvage options. Data on the efficacy and safety of chimeric antigen receptor T (CAR-T) cell therapy in this population remains limited.
We retrospectively analyzed 25 adult patients with relapsed or refractory Burkitt lymphoma who received CAR T-cell therapy. Clinical data, treatment responses, and survival outcomes were collected from medical records. Bridging therapy and lymphodepleting regimens varied based on disease status. Treatment-related toxicities and CAR-T expansion were monitored. Primary endpoints included efficacy, safety, and survival. Risk factors associated with treatment outcomes were explored using univariate analyses.
One month objective response rate (ORR) was 52%(13/25)(95%CI: 31.3-72.2), with a complete response rate (CRR) of 28% (7/25). Sixteen patients (64%) received sequential consolidation therapy including 9 who received a second CAR-T infusion, and 7 who proceeded to autologous or allogeneic hematopoietic stem cell transplantation. The median follow-up time was 26.10 months (range 14.50-57.17). The median OS was 5.49 months(95%CI 1.74-9.25), and the median PFS was 2.96(95%CI 1.62-4.3)months. At last follow-up(2024-08-22), 28% achieved disease-free survival, with one patient disease-free for 5 years.
CAR-T therapy shows promising activity in relapsed/refractory Burkitt lymphoma, but its effectiveness is limited by short response duration. High-risk features may predict poor outcomes, and a higher number of long-term survivors were observed in patients who received transplant sequential consolidation. However, due to the small sample size, larger studies are needed to validate these findings.
成人复发或难治性（R/R）伯基特淋巴瘤（BL）具有侵袭性，且缺乏标准化的挽救治疗方案。嵌合抗原受体T（CAR-T）细胞疗法在该人群中的疗效和安全性数据仍然有限。
我们回顾性分析了25例接受CAR-T细胞疗法的复发或难治性伯基特淋巴瘤成年患者。从病历中收集临床数据、治疗反应和生存结果。根据疾病状态，桥接治疗和淋巴细胞清除方案有所不同。监测治疗相关毒性和CAR-T扩增情况。主要终点包括疗效、安全性和生存情况。使用单因素分析探索与治疗结果相关的危险因素。
1个月时的客观缓解率（ORR）为52%（13/25）（95%CI：31.3-72.2），完全缓解率（CRR）为28%（7/25）。16例患者（64%）接受了序贯巩固治疗，其中9例接受了第二次CAR-T输注，7例进行了自体或异基因造血干细胞移植。中位随访时间为26.10个月（范围14.50-57.17）。中位总生存期（OS）为5.49个月（95%CI 1.74-9.25），中位无进展生存期（PFS）为2.96个月（95%CI 1.62-4.3）。在最后一次随访（2024-08-22）时，28%的患者实现了无病生存，其中1例患者无病生存5年。
CAR-T疗法在复发/难治性伯基特淋巴瘤中显示出有前景的活性，但其有效性受到缓解持续时间短的限制。高危特征可能预示预后不良，在接受移植序贯巩固治疗的患者中观察到更多的长期生存者。然而，由于样本量小，需要更大规模的研究来验证这些发现。
